tiprankstipranks
Polaryx Therapeutics, Inc. (PLYX)
NASDAQ:PLYX
US Market
PLYX
Polaryx Therapeutics, Inc.
RESEARCH TOOLSreports

Polaryx Therapeutics, Inc. (PLYX) Price & Analysis

16 Followers

PLYX Stock Chart & Stats

$2.31
$0.16(7.44%)
At close: 4:00 PM EDT
$2.31
$0.16(7.44%)
Day’s Range― - ―
52-Week Range$1.86 - $48.91
Previous Close$2.31
Volume204.17K
Average Volume (3M)N/A
Market Cap
$115.14M
Enterprise Value$106.28M
Total Cash (Recent Filing)$5.14M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-1.95
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding49,845,993
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-9.82
Price to Book (P/B)362.98
Price to Sales (P/S)0.00
P/FCF Ratio-420.14
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-13.32
Forecast
1Y Price Target
$7.00
Price Target Upside203.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A

Polaryx Therapeutics, Inc. News

Polaryx initiated with a Buy at Lucid Capital
Polaryx initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of Polaryx (PLYX) with a Buy rating and $7 price target The company is...
6d ago
PLYX
Polaryx initiated with a Buy at H.C. Wainwright
Polaryx initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Polaryx (PLYX) with a Buy rating and $7 price target...
24d ago
PLYX
Polaryx Therapeutics Announces Chief Medical Officer Resignation
Polaryx Therapeutics Announces Chief Medical Officer Resignation
Polaryx Therapeutics, Inc. ( ($PLYX) ) just unveiled an announcement. On July 19, 2026, Polaryx Therapeutics, Inc. announced...
12d ago
8K
PLYX
Polaryx Sets 2026 Virtual Annual Shareholder Meeting
Polaryx Sets 2026 Virtual Annual Shareholder Meeting
Polaryx Therapeutics, Inc. ( ($PLYX) ) has issued an announcement. On July 16, 2026, Polaryx Therapeutics, Inc.’s board...
16d ago
8K
PLYX
Polaryx Therapeutics Raises $10 Million to Fund SOTERIA Trial
The latest update is out from Polaryx Therapeutics, Inc. ( ($PLYX) ). On May 28, 2026, Polaryx Therapeutics...
2M ago
8K
PLYX
Polaryx receives U.S. FDA Fast Track Designation for PLX-200
Polaryx receives U.S. FDA Fast Track Designation for PLX-200
Polaryx (PLYX) Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD,...
3M ago
PLYX
Polaryx’s PLX-200 granted FDA Fast Track Designation in LINCL/CLN2
Polaryx’s PLX-200 granted FDA Fast Track Designation in LINCL/CLN2
Polaryx (PLYX) announced that the FDA has granted Fast Track Designation to PLX-200 for the treatment of Late-Infantile...
5M ago
PLYX
Polaryx Therapeutics, Inc trading resumes
Polaryx Therapeutics, Inc trading resumes
11:07 EDT Polaryx (PLYX) Therapeutics, Inc trading resumes Published first on TheFly – the ultimate source for real-time,...
5M ago
PLYX
Polaryx Therapeutics, Inc trading halted, volatility trading pause
Polaryx Therapeutics, Inc trading halted, volatility trading pause
11:02 EDT Polaryx (PLYX) Therapeutics, Inc trading halted, volatility trading pause Published first on TheFly – the ultimate...
5M ago
PLYX
Maxim starts Polaryx at Buy, sees PLX-200 as differentiated
Maxim starts Polaryx at Buy, sees PLX-200 as differentiated
As previously reported, Maxim initiated coverage of Polaryx (PLYX) with a Buy rating and $10 price target The...
5M ago
PLYX
Polaryx commits to patients with rare pediatric lysosomal storage disorders
Polaryx commits to patients with rare pediatric lysosomal storage disorders
Polaryx (PLYX) Therapeutics joins the global rare disease community in raising awareness and supporting patients, families, caregivers, and...
5M ago
PLYX
Polaryx initiated with a Buy at Maxim
Polaryx initiated with a Buy at Maxim
Maxim initiated coverage of Polaryx (PLYX) with a Buy rating and $10 price target Published first on TheFly...
5M ago
PLYX

PLYX FAQ

What was Polaryx Therapeutics, Inc.’s price range in the past 12 months?
Polaryx Therapeutics, Inc. lowest stock price was $1.86 and its highest was $48.91 in the past 12 months.
    What is Polaryx Therapeutics, Inc.’s market cap?
    Polaryx Therapeutics, Inc.’s market cap is $115.14M.
      When is Polaryx Therapeutics, Inc.’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Polaryx Therapeutics, Inc.’s earnings last quarter?
      Currently, no data Available
      Is Polaryx Therapeutics, Inc. overvalued?
      According to Wall Street analysts Polaryx Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Polaryx Therapeutics, Inc. pay dividends?
        Polaryx Therapeutics, Inc. does not currently pay dividends.
        What is Polaryx Therapeutics, Inc.’s EPS estimate?
        Polaryx Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Polaryx Therapeutics, Inc. have?
        Polaryx Therapeutics, Inc. has 49,845,993 shares outstanding.
          What happened to Polaryx Therapeutics, Inc.’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Polaryx Therapeutics, Inc.?
          Currently, no hedge funds are holding shares in PLYX
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Polaryx Therapeutics, Inc. Stock Smart Score

            5
            Neutral
            1
            2
            3
            4
            5
            6
            7
            8
            9
            10

            Analyst Consensus

            Moderate Buy
            Average Price Target:
            $7.00 (203.03% Upside)

            Blogger Sentiment

            Bullish
            PLYX Sentiment 100%
            Sector Average 61%

            Insider Transactions

            Bought Shares
            Worth $360.0K over
            the Last 3 Months

            News Sentiment

            Very Bullish
            Bullish news 100%
            Bearish news 0%

            Fundamentals

            Return on Equity
            ―
            Trailing 12-Months
            Asset Growth
            -21.09%
            Trailing 12-Months
            Top Smart Score Stocks >

            Company Description

            Polaryx Therapeutics, Inc.

            Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.

            PLYX Stock 12 Month Forecast

            Average Price Target

            $7.00
            ▲(203.03% Upside)
            {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","36":"$36","9.75":"$9.75","18.5":"$18.5","27.25":"$27.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,9.75,18.5,27.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.58,2.92,3.26,3.6,3.94,4.279999999999999,4.62,4.96,5.3,5.64,5.9799999999999995,6.32,6.66,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.58,2.92,3.26,3.6,3.94,4.279999999999999,4.62,4.96,5.3,5.64,5.9799999999999995,6.32,6.66,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.58,2.92,3.26,3.6,3.94,4.279999999999999,4.62,4.96,5.3,5.64,5.9799999999999995,6.32,6.66,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":35,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":35,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":35,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":35,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":35,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":35,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":35,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.88,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
            Detailed Analyst Forecast >
            Similar Stocks
            Company
            Price & Change
            Follow
            ALDX
            Aldeyra Therapeutics
            ―
            ―
            ATRA
            Atara Biotherapeutics
            ―
            ―
            CUE
            Cue Biopharma
            ―
            ―
            CNTB
            Connect Biopharma Holdings
            ―
            ―
            PEPG
            PepGen Inc.
            ―
            ―
            Compare PLYX Stocks >

            Ownership Overview

            49.07%47.70%
            49.07% Insiders
            ― Mutual Funds
            ― Other Institutional Investors
            47.70% Public Companies and
            Individual Investors
            Detailed Ownership Overview >
            Popular Stocks